<DOC>
	<DOCNO>NCT00546364</DOCNO>
	<brief_summary>The purpose study assess effect ixabepilone plus capecitabine docetaxel plus capecitabine shrink slow growth metastatic breast cancer woman . The safety combination therapy also evaluate .</brief_summary>
	<brief_title>Randomized Study Evaluating Ixabepilone Plus Capecitabine Docetaxel Plus Capecitabine Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Participants metastatic breast cancer Measurable disease Up 1 chemotherapy regimen acceptable . Participants receive paclitaxel neoadjuvant adjuvant set acceptable , last dose paclitaxel receive 12 month less treatment . There timeframe prior paclitaxel metastatic setting . Human epidermal growth factor receptor 2positive participant allow progressed receive treatment trastuzumab lapatinib Eastern Cooperative Oncology Group Performance status 01 Age young 18 year Women childbearing potential must use adequate method contraception avoid pregnancy throughout study least 4 week last dose investigational product More 1 chemotherapy regimen treatment metastatic breast cancer Prior treatment epothilone , capecitabine , docetaxel Prior radiation must include 30 % major bone marrowcontaining area ( pelvis , lumbar spine ) . If prior radiation le 30 % , minimum interval 2 week must allow last radiation treatment administration study medication . There must least 1 week focal/palliative radiation administration study medication . Any current previous history brain and/or leptomeningeal metastasis Neuropathy great Grade 2 Any concurrent malignancy nonmelanoma skin cancer carcinoma situ cervix Uncontrolled diabetes mellitus Chronic hepatitis HIVpositive status Administration trastuzumab , lapatinib , bevacizumab , systemic treatment cancer must discontinue 28 day prior study medication . Hormonal anticancer agent must discontinue least 14 day prior study medication . Hormonal replacement therapy acceptable Biphosphonates palliation bone metastases allow initiated least 7 day study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>